MANJUSHA GAGLANI to Antibodies, Viral
This is a "connection" page, showing publications MANJUSHA GAGLANI has written about Antibodies, Viral.
Connection Strength
1.674
-
Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. J Infect Dis. 2014 Jun 01; 209(11):1705-14.
Score: 0.286
-
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
Score: 0.153
-
Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
Score: 0.153
-
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
Score: 0.149
-
Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study. Clin Infect Dis. 2024 07 19; 79(1):96-107.
Score: 0.149
-
Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022. Influenza Other Respir Viruses. 2024 07; 18(7):e13339.
Score: 0.148
-
Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial. Clin Infect Dis. 2023 02 08; 76(3):e1168-e1176.
Score: 0.135
-
Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial. Clin Infect Dis. 2021 12 06; 73(11):1973-1981.
Score: 0.124
-
Reduced serologic sensitivity to influenza A virus illness among inactivated influenza vaccinees. Vaccine. 2016 06 24; 34(30):3443-6.
Score: 0.084
-
Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. Vaccine. 2016 Feb 10; 34(7):981-8.
Score: 0.083
-
Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nat Commun. 2024 Jan 04; 15(1):254.
Score: 0.036
-
Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses. Clin Infect Dis. 2023 05 24; 76(10):1822-1831.
Score: 0.034
-
Multiplex Detection of Antibody Landscapes to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Influenza/Common Human Coronaviruses Following Vaccination or Infection With SARS-CoV-2 and Influenza. Clin Infect Dis. 2022 10 03; 75(Suppl 2):S271-S284.
Score: 0.033
-
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection. Clin Infect Dis. 2022 08 24; 75(1):e827-e837.
Score: 0.033
-
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022 05 12; 386(19):1855-1857.
Score: 0.032
-
Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2021 06 15; 223(12):2062-2071.
Score: 0.030
-
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis. 2010 Mar 17; 10:71.
Score: 0.014